Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2017 Complete Response Letters: Fewer Than 2016, Still More Than Years Past

Executive Summary

US FDA's complete response letters dropped from 41 in 2016 to 30 in 2017; quality issues as share of total letters continued to climb.

Advertisement

Related Content

Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen
Public Complete Response Letters? Don’t Hold Your Breath
Q&A With US FDA Commissioner Scott Gottlieb
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
Novel Approvals Were Fewer But Faster At US FDA In 2016
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
Reader, Be Wary: Sponsors Keep Most 'Complete Response' Letter Content Under Wraps, FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel